The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM ...

Using technologies like electron microscopy (EM) it is possible to capture molecular mechanisms in great detail, but not when these mechanisms are currently moving. The field of cryomicroscopy ...

Each year, about 14,000 people in the United States are diagnosed with glioblastoma, one of the deadliest primary brain tumors. With standard treatments of surgery, radiation, and chemotherapy ...

Scientists have discovered that a protein once thought to be just a cellular "courier" actually helps plants survive drought. This motor protein, myosin XI, plays a critical role in helping leaves ...

Myosin II is a biomolecular machine that is responsible for muscle contraction. Myosin II motors act cooperatively: during muscle contraction, multiple motors bind to a single actin filament and pull ...